Stocks Hitting 52-Week Lows

shares touched a new 52-week low of $1.18 on failed Phase 2 MRX-6 cream trial.

shares reached a new 52-week low of $2.21. Onconova Therapeutics shares have dropped 83.63% over the past 52 weeks, while the S&P 500 index has gained 13.92% in the same period.

shares fell 15.99% to touch a new 52-week low of $16.03 after the company reported downbeat Q4 results.

shares dropped 2.80% to reach a new 52-week low of $7.64. Natural Resource Partners' trailing-twelve-month EPS is $0.94.